RESUMO
Gender-affirming hormone therapy is a safe and effective way to improve quality of life and mental health outcomes for transgender adolescents. Access to this treatment is limited, with the most vulnerable transgender people experiencing the greatest gaps in care. Because some psychiatrists help transgender patients receive needed medical interventions, we analyze the ethical values they must balance when deciding whether to provide hormone therapy to patients who seek it.
Assuntos
Prescrições de Medicamentos , Identidade de Gênero , Serviços de Saúde para Pessoas Transgênero/ética , Hormônios , Psiquiatria/ética , Procedimentos de Readequação Sexual/ética , Pessoas Transgênero , Adolescente , Tomada de Decisões/ética , Ética Médica , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Masculino , Saúde Mental , Relações Médico-Paciente/ética , Qualidade de VidaRESUMO
Phototherapy can be a safe and effective treatment for various skin diseases in children. Special considerations governing the use of this treatment modality in pediatric populations include patient, family, and facility-based factors that are oriented around heightened concerns with regard to safety and tolerability of treatment. Although phototherapy has been found to be effective in a wide range of dermatologic conditions affecting pediatric populations, including psoriasis, atopic dermatitis, pityriasis lichenoides, cutaneous T-cell lymphoma, and vitiligo, there is need for additional research on other conditions in which phototherapy has shown promise.
Assuntos
Seleção de Pacientes , Dermatopatias/radioterapia , Terapia Ultravioleta , Adolescente , Criança , Pré-Escolar , Dermatite Atópica/radioterapia , Humanos , Lactente , Recém-Nascido , Linfoma Cutâneo de Células T/radioterapia , Pitiríase Liquenoide/radioterapia , Psoríase/radioterapia , Terapia Ultravioleta/efeitos adversos , Terapia Ultravioleta/métodos , Vitiligo/radioterapiaRESUMO
We report two girls, ages 9 and 17 years, with a clinical diagnosis of neurofibromatosis 1 (NF-1) who presented with ill-defined, blanchable, erythematous patches on the dorsal feet and ankles. We hypothesized that these patches were a rare cutaneous finding in NF-1 that exist on a clinical and histopathologic spectrum with previously described NF-1 vascular lesions including blue-red macules and skin ulceration due to NF-1 vasculopathy. We suggest that these lesions be called neurovascular stains (NVSs) to unify their clinical and histopathologic features.